Neuron-specific enolase (EC 4.2.1.11; NSE), a glycolytic enzyme produced by neuronal and neuroendocnne cells, is used as a tumor marker of neuroendocrine cancers, especially small-cell lung cancer. We have evaluated the behavior of NSE in nonmalignant liver diseases in 161 patients who underwent a thorough clinical and biochemical evaluation. Nine of the 161 patients (5.6%)-three of the 86 cirrhotic patients (3.5%), and six of the 75 noncirrhotics (8%).-had abnormal concentrations of NSE. Of the numerous clinical and analytical factors considered, none correlated significantly with NSE. The low falsepositive rate, similar to or even lower than for other benign diseases, and the absence of association with the numerous characteristics of liver diseases that we studied, support the lack of any substantial metabolism of NSE by the liver. Consequently, the coexistence of a benign liver disease does not limit the usefulness of this enzyme as a tumor marker.
enolase (NSE), originally extracted from bovine brain, was later characterized as a neuronal isomer of the widely distributed glycolytic enzyme enolase (2-phospho-D-glycerate hydro-lyase; EC 4.2.1.11) (1) . Enolase is present in the cells of all organs as the three dimeric isoen.zymes (aa, aT, and ri.), except in striated muscles, where the isoenzymes are formed of a distinct 13-subunit. Because rr is the main form present in neurons, where it corresponds to the neuron-specific protein 14.3.2, it was called neuron-specific enolase (NSE), whereas the aa-isoenzyme has been designated as nonneuronal enolase (NNE) (2) . In a wider sense, these terms now designate the concentration of the corresponding enolase subunit. Thus NSE represents the concentration of the r-subunits, which are contained in the ri form and in the heterodimeric form ar, and NNE the concentration of the a-subunits of aa isoenzyme and ar isoen.zyme (3) .
It was at first considered that the gene coding for NSE was restricted to neurons, and that NSE was present only in the central nervous system. NSE was later found in endocrine (APUD, amine precursor uptake and decarboxylation) cells (4). Tapia et al. (5) found NSE in a (3, 9, (12) (13) (14) (15) (16) . Some authors have improved the specificity of the test by using the NSEINNE ratio (3, 7) .
The incidence of false-positive results in nonneoplastic diseases has not been well studied, and most of these reports refer to lung processes with rates of 0-30%, usually with moderate values (8, 9, 11, 17) . In other benign diseases the reports are very scanty, especially in liver diseases, where the rate of false-positive results is low; these also involve only moderately increased values (17, 18) . Moreover, no study has included a full evaluation of the patients.
We undertook the present study, as a part of a more extensive work on several tumor markers, to investigate the behavior of NSE in benign liver diseases through an exhaustive evaluation from both the clinical and the laboratory standpoint.
Materials and Methods
We studied 161 patients with benign liver diseases, 120 men and 41 women, ages 16 to 87 years (mean 50.7 years). The patients were divided into the following diagnostic groups: cirrhosis (86 patients), fibrosis without histological criteria for cirrhosis (15) , steatosis (six), chronic active hepatitis (15) , chronic persistent hepatitis (15) , minimal changes in the liver biopsy (nine), and miscellaneous (15) . The miscellaneous group comprised two cases of acute viral hepatitis B, two of granulomatous hepatitis, one of drug-induced hepatitis, two of intrahepatic cholestasis, one of choledocholithiasis with obstructive jaundice, one of liver microhamartomas (von Meyenberg complex), one of myeloid metaplasia, and five cases without a precise diagnosis.
All patients were included in a study protocol within 24-48 h from admission. Simultaneous blood and urine specimens were collected for all the laboratory determinations. The samples that were not processed immediately were frozen at -20 #{176}C until processing. NSE was measured by radioimmunoassay with a commercial kit (Pharmacia Diagnostics AB, Uppsala, Sweden Resufts Table 1 shows the NSE false positives and the descriptive statistics in every diagnostic group. The patients' mean concentration of NSE was 5.67 zgfL, substantially lower than the upper limit of normal for healthy subjects. The male patients had higher concentrations of NSE than did the women (P = 0.048). Age had no influence on NSE concentrations. We also found no significant differences between cirrhotics and noncirrhotics or with the Child's classification of cirrhosis. Similarly, neither the diagnosis nor the etiology of the diseases studied had any significant influence on NSE concentrations in serum. Table 2 shows that none of various diverse quantitative measures significantly correlated with NSE. In addition neither urinary bilirubin, urobilinogen, alcoholic or smoking habitus, previous hepatic decompensations of various types, viral markers, cholelithiasis, portal hypertension, drugs, reason for admission, spider veins, telangiectasis, ascites, hepato-or splenomegaly, nor nutritional variables had any significant correlation with the concentrations of NSE in serum.
Discussion
These results illustrate that benign liver diseases had little influence on NSE in serum. The mean concentration of NSE (5.67 /.Lg/L), substantially lower than the upper limit of normal, and the low rate of abnormal values (5.6%), support this conclusion. Moreover, the absence of any correlation with the numerous variables analyzed is an additional verification. (20) found proliferation of nerve fibers in the enlarged portal area of the patients with chronic active hepatitis and in the fibrous septa of cirrhotic liver, suggesting that, in chronic liver diseases, intrahepatic nerve fibers change their distribution accompanying the structural changes in the hepatic lobules. Ledig et al. (21) found both NSE and NNE in increased activities in blood cells of alcoholic patients with liver injury.
However, in an extensive review of the literature, we have not found any report specifically devoted to the study of serum NSE in benign liver diseases. In a global evaluation with other benign processes, Ruibal et al. (17) found abnormal results in 11.4% of 167 patients with a variety of liver diseases; they used a threshold for normal of 18 gfL. Also, in a global evaluation with malignant and nonmalignant diseases, Cooper et al. (18) , using a threshold of 13 p.g/L, found a 15.6% rate of false-positive results in 45 patients with benign gastrointestinal and hepatic diseases, without detailing the patients' respective numbers or diagnosis. As has been mentioned above, the rate we observed is still lower, despite our use of a threshold even lower than those of these authors.
We conclude that the presence of a benign liver disease does not represent an important factor to consider when investigating the cause of increased concentrations of NSE in serum. The false-positive rate is low and similar to, or even lower than, those of other benign diseases. In our opinion, the liver plays no significant role in the metabolism of NSE.
